IRAG
LGND icon

Investment Research & Advisory Group’s Ligand Pharmaceuticals LGND Stock Holding History

Investment Research & Advisory Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.1K Buy
+206
New +$48.5K 0.02% 121

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
IP
Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Investment Research & Advisory Group's LGND Position: Q2 2026 in Review

Investment Research & Advisory Group opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 206 shares worth $65.1K. The stake represents 0.02% of the portfolio and ranks #121 among its holdings.

113 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Investment Research & Advisory Group held 206 shares of Ligand Pharmaceuticals worth $65.1K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Investment Research & Advisory Group position in Q2 2026.
  • Ligand Pharmaceuticals made up 0.02% of Investment Research & Advisory Group's portfolio in Q2 2026, its #121 holding.
  • 113 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Investment Research & Advisory Group's 13F filing for Q2 2026, filed 23 Jul 2026.